Regulated information

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

BALO : Notice of meeting

Shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 28, 2024 at 11 a.m. at the Company's registered office, Magny-Vernois 70 200 LURE, in order to deliberate on the following agenda and draft resolutions

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

Rémunération et politique des dirigeants - mai 2023 (french)

Rémunération et politique des dirigeants
Résultats des votes de l’Assemblée Générale Mixte du 25 mai 2023

Vetoquinol - assemblée générale mixte - 25 mai 2023 : résultat du scrutin

Assemblée générale - Vetoquinol SA 25 mai 2023

Ordre du jour : 
1. PARTIE ORDINAIRE
2. PARTIE EXTRAORDINAIRE

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social – record date

Conformément aux dispositions des articles L233-8-II du Code de Commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers

Q1 2023 Sales: €145M

Vetoquinol recorded sales of €145 million for the first three months of the 2023 financial year, up 7.7% on a reported basis and 7.2% at constant exchange rates.

BALO : Avis de convocation / avis de réunion

Mesdames et Messieurs les actionnaires sont convoqués le jeudi 25 mai 2023 à 11h00 au siège social, Magny-Vernois 70200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions ci-après.

Availability of the 2022 universal registration document

On 13 April 2023, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

2022 ANNUAL RESULTS

Annual sales: €540m (up 3.6% as reported)
Essentials sales: €304m (up 4.5% as reported)
EBIT before depreciation of acquired assets: €99m (18.3% of sales)
Net income - Group share: €48m (8.9% of sales)
EBITDA: €118m (21.9% of sales)
Free cash-flow: €63m

Annual sales 2022

Total group Sales: €540 million (up 3.6% as reported)
Annual Sales of Essential products: €304 million (up 4.5% as reported)

First nine months 2022 sales: €405M

In line with year-end outlook

2022 HALF YEAR RESULTS Additional information on the Group’s strategy

Following the conference call organised on 15 September 2022 to present its half-year results, Vetoquinol would like to provide some additional information on the strategy implemented and its outlook.

2022 HALF YEAR RESULTS

Sales: €271m (up 6.0% as reported)
Essentials sales: €154m (up 9.8% as reported)
EBIT before depreciation of acquired assets: €52m (19.0% of sales)
Net income - Group share: €21m (7.9% of sales)
EBITDA: €62m (22.9% of sales)

H1 2022 Sales

H1 2022 Sales: €271m, up 6.1%
+2.0% on a like-for-like basis
H1 2022 Essentials Sales: €154m, up 9.8%
+6.8% on a like-for-like basis

Remuneration vote results - AG may 2022

Vote results - AG may 19, 2022

Information regarding the total number of voting rights and shares making of the share capital - 12 may 2022

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers»

Balo new information

Balo new information

Number of voting rights and shares making of the share capital

Information regarding the total number of voting rights and shares making of the share capital  - J-21 before AGM as per articles L233-8-II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

Annual general meeting 2022 - brochure

Availability of the 2021 universal registration document

Vetoquinol informs that it has filed its 2021 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 22th, 2022.

Vote by post / proxy form

Vote by post of proxy form for annual general meeting on May 19, 2022

General annual meeting - may 19 2022

Annual General Meeting on May 19, 2022 - convocation

Q1 2022 SALES: €135M

Q1 2022 SALES: €135M
(UP 5.5% AS REPORTED, UP 2.2% AT CONSTANT EXCHANGE RATES)
Q1 2022 ESSENTIALS SALES: €77M
(UP 8.1% AS REPORTED, UP 5.5 AT CONSTANT EXCHANGE RATES)

2021 Annual results

ALL FINANCIAL INDICATORS UP.
Annual sales: €521m (up 21.9% as reported).
Essentials sales: €296m (up 34.0% as reported).
EBIT before depreciation of acquired assets: €101m (up 54.5%).
Net income - Group share: €63m (up 226.9%).

Double-digit growth in 2021

Total Group Sales: €521 million (up 21.9% as reported)
Annual Sale of Essential products: €296 million (up 34.0% as reported)

Third quarter revenues: €132 million

2021 first half results

2021 Half year results

Rémunération et politique des dirigeants (french) Résultats des votes de l’Assemblée Générale Mixte du 27 mai 2021

Résultats du scrutin de l'Assemblée Générale mixte du 26 mai 2020 (french) Résultats du scrutin

Assemblée générale mixte du 27 mai 2021 (french) Présentation de l'Assemblée Générale annuelle mixte du 27 mai 2021

Formulaire de vote 2021 (french) Assemblée Générale Mixte du 27 mai 2021

Avis de réunion valant avis de convocation (french)

Availability of the 2020 universal registration document

Vetoquinol informs that it has filed its 2020 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 28th, 2021.

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le jeudi 27 mai 2021 à 14h00, au siège social, Magny-Vernois 70 200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

Q1 2021 sales

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

Vetoquinol wins the Animal Pharm’s award for best European company 2020

February 8th, 2021 (Lure, France) - Vetoquinol announced today it has been awarded “Best European Company 2020” by Animal Pharm.

Vetoquinol acquires the rights for Profender® from Elanco Animal Health for Canada

February 8th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Canadian rights to Profender® product family from Elanco Animal Health.

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

Orion Animal Health and Vetoquinol expand collaboration - Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania

Orion Animal Health and Vetoquinol are expanding their collaboration with new distribution agreements.

Vetoquinol acquires the rights for Drontal® and Profender® families from Elanco animal health for Australia

January 11th, 2021 (Lure, France) - Vetoquinol announced today the acquisition of the Australian rights to Drontal® and Profender® product families from Elanco Animal Health.

Q3 2020 sales: €114.5 million* (Up 14.3%)

Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year.

VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare.

Vetimpress delivering digital solutions to farm vets with a growing network of partnerships

September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions.
 

Vetoquinol finalizes the acquisition of Profender® and Drontal® product families

September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020.

2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales)

At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission

June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health.

Rémunération et politique des dirigeants (french) Résultats des votes de l’Assemblée Générale Mixte du 26 mai 2020

Combined Ordinary and Extraordinary General Meeting of May 26, 2020 The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 26, 2020 in Lure, chaired by Etienne Frechin. The shareholders did not physically attend this meeting in view of the restrictions on gatherings due to the health crisis in France.

Résultats du scrutin de l'Assemblée Générale mixte du 26 mai 2020 (french) Résultats du scrutin

Assemblée Générale Annuelle Mixte (french) 26 mai 2020

Brochure Vetoquinol AGM en huis clos Mesdames et Messieurs les actionnaires,

Dominique Derveaux appointed Group Chief Operations Officer Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin.

Availability of the 2019 universal registration document

Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020.

Q1 2020 sales €103.4 million (Up 13.7%)

Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates.

Formulaire de vote

Formulaire de vote - Assemblée générale mixte -  26 mai 2020 - siège social Magny-Vernois 70200 LURE

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 26 mai 2020 à 14h45, au siège social, Magny-Vernois 70 200 LURE, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales)

At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon.

Covid-19: Vetoquinol donates masks to neighboring healthcare facilities

Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions.

Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK

February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health.

2019 sales: €396.0 million (Up 7.6%)

The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates.

Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement

December 12, 2019 (Lure, France) - Vetoquinol S.A. and Klox Technologies Limited, a subsidiary of Klox Technologies Inc., have entered into an exclusive global licensing agreement, excluding the People’s Republic of China.

Q3 2019 sales: €100.2 million (Up 11.0%)

The Vetoquinol Group posted sales of €100.2 million for the third quarter of 2019, up 11.0% as reported and up 9.4% at constant exchange rates compared to the same period last year.

First half 2019 results

At its meeting on July 24, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2019 financial statements.

Vetoquinol announces a new milestone in its industrial strategy

Vetoquinol, a leading global animal health player, today announces a plan to reorganize its production facilities in Europe. This decision is in line with the Group’s strategy of streamlining operations in order to improve its response to customer needs, whether vets, breeders or pet owners.

Monthly information regarding the total number of voting rights and shares making of the share capital - June 2019

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Monthly information regarding the total number of voting rights and shares making of the share capital - May 2019

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Combined ordinary and extraordinary general meeting May 21, 2019

The Combined Ordinary and Extraordinary General Meeting of Vetoquinol shareholders was held on Tuesday May 21, 2019 in Lure, chaired by Etienne Frechin.

Résultats du scrutin de l'Assemblée générale du 24 mai 2016 (french)

Assemblée générale mixte du 24 mai 2016

Assemblée Générale Annuelle Mixte

21 mai 2019

Monthly information regarding the total number of voting rights and shares making of the share capital - March 2019

As per article 223.16 of the « Règlement Général de « L’Autorité des Marchés Financiers » 

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2018 (french version)

Q1 2019 sales: €90.9 million (up 3.7%)

Vetoquinol Group sales for Q1 2019 amounted to €90.9 million, up 2.3% at constant exchange rates and up 3.7% as reportedfrom the same period last year.

Vetoquinol finalizes acquisition of Clarion Biociencias in Brazil

Lure (France), April 16, 2019 - Vetoquinol today confirms the completion of its acquisition of Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Formulaire de vote

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

Vetoquinol signs agreement to acquire Clarion Biociênciasin Brazil

On April 3rd, Vetoquinol signed an agreement to acquire Clarion Biociências, a Brazilian veterinary laboratory based in the state of Goiás.

Growth in all financial indicators in 2018. Essentials products sales: €179.4M (up 9.1% at constant exchange rates). Net income group share €36.3M (up 4.0%)

At its meeting on March 19, 2019, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2018 financial statements.

2018 sales: up 3.2% to €367.9 million

9.1% GROWTH IN ESSENTIALS PRODUCTS AT CONSTANT EXCHANGE RATES

Q3 2018 sales: €90.2 million Vetoquinol wins second prize for CSR in the Gaia Rating

In the first nine months of 2018, Vetoquinol recorded sales of €268.1 million, up 3.8% at constant exchange rates and 0.4% as reported.

Résultats du scrutin de l'Assemblée générale du 24 mai 2016 (french)

Assemblée générale mixte du 24 mai 2016

Vetoquinol takes a major step towards digital innovation by acquiring an equity interest in Farmvet Systems Ltd

Vetoquinol, a leading global animal health company, has acquired a majority interest in Farmvet Systems Ltd. A thriving start-up based in Northern Ireland, Farmvet Systems digital know-how enables the strengthening of the role of the veterinary practitioner on cattle farms.

First half 2018 results

At its meeting on July 25, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited first half 2018 financial statements.

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

Vetoquinol publishes its half-yearly financial report relative to fiscal year 2018

Résultats du scrutin de l'Assemblée générale du 24 mai 2016 (french)

Assemblée générale mixte du 24 mai 2016

Combined ordinary and extraordinary general meeting May 29, 2018

The Combined Ordinary and Extraordinary General meeting was held on Tuesday May 29, 2018 in Lure, chaired by Etienne Frechin.

Assemblée Générale Mixte (french)

28 mai 2018 à 14h30

Avis de réunion valant avis de convocation (french)

Mesdames et Messieurs les actionnaires sont convoqués le mardi 30 mai 2017 à 15h30, au siège social, 34, rue du Chêne Sainte-Anne 70200 Lure, en Assemblée générale mixte, à l’effet de délibérer sur l’ordre du jour et les projets de résolutions suivants :

Formulaire de vote (French)

ASSEMBLEE GENERALE MIXTE du 30 MAI 2017 à 15h30

Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2017 (french version)

The registration document of Vetoquinol relative to fiscal year 2017, including the annual financial report relative to fiscal year 2017, was filed with the Autorité des marchés financiers (“the AMF”) on April 23, 2018. 

Q1 2018 sales: €87.6M like-for-like growth up 5.6%, 0.4% as reported growth of essentials products: up 6.8% as reported

Vetoquinol posted Q1 2018 consolidated sales of €87.6 million, up 5.6% like for like and 0.4% as reported, compared to the same period last year. Negative currency impacts of 5.2% were mainly related to the US and Canadian dollars and the Indian rupee. 

Strong growth in all key financial indicators in 2017 ebit up 9.4% to €46.0 million net income - group share up 25.2% to €34.8 million

At its meeting on March 14, 2018, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the audited 2017 financial statements.